Premium
Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Krüppel‐like factor 4‐dihydropyrimidinase‐like 2A (KLF4‐DPYSL2A) axis
Author(s) -
Noura Mina,
Morita Ken,
Kiyose Hiroki,
Okuno Yukiko,
Matsuo Hidemasa,
Koyama Asami,
NishinakaArai Yoko,
Kamikubo Yasuhiko,
Adachi Souichi
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17557
Subject(s) - klf4 , cancer research , in vivo , myeloid , krüppel , cd33 , cellular differentiation , differentiation therapy , acute promyelocytic leukemia , immunology , medicine , biology , cell culture , cd34 , transcription factor , stem cell , microbiology and biotechnology , retinoic acid , genetics , gene , sox2
Summary Differentiation therapy is a less toxic but still a very effective treatment for a subset of acute myeloid leukaemia (AML) cases. With the goal to identify novel compounds that can effectively and safely induce the terminal differentiation of non‐acute promyelocytic leukaemia (APL) AML cells, we performed a chemical screening and identified albendazole (ABZ), a widely used anti‐helminthic drug, as a promising lead compound that can differentiate non‐APL AML cells by stimulating the Krüppel‐like factor 4‐dihydropyrimidinase‐like 2A (KLF4‐DPYSL2A) differentiation axis to the monocytes. Our in vitro and in vivo findings demonstrate that ABZ is an attractive candidate drug as a novel differentiation chemotherapy for patients with non‐APL AML.